<DOC>
	<DOCNO>NCT01323244</DOCNO>
	<brief_summary>The purpose study investigate efficacy treatment TMC435 combination peginterferon alfa-2a ribavirin patient clear hepatitis C infection peginterferon alfa-2a ribavirin alone within previous trial conduct Tibotec , participate Tibotec trial antiviral direct hepatitis C virus ( HCV ) evaluate short period time .</brief_summary>
	<brief_title>A Study TMC435 Combination With Peginterferon Alfa-2A Ribavirin Hepatitis C Virus Genotype-1 Infected Patients Who Participated Control Group TMC435 Study</brief_title>
	<detailed_description>This roll trial TMC435 patient genotype-1 HCV infection participate control ( placebo ; substance contain active medication ) group TMC435 trial receive treatment 14 day antiviral direct HCV previous Tibotec trial . Patients study receive TMC435 combination peginterferon alfa-2a ( Pegasys ) ribavirin ( Copegus ) follow peginterferon alfa-2a ribavirin alone . The total treatment duration 24 48 week , depend patient respond treatment previous response peginterferon alfa-2a ribavirin alone . The study doctor inform patient take study medication stop taking . After patient stop take study medication , contiue come doctor 's office study visit 24 week ( case 48 week ) end treatment . The total duration study 78 week ( include screen ) . Patients monitor safety throughout study . Study assessment visit may include limited : blood urine collection testing , electrocardiogram ( ECG ) assessment ( measurement electrical activity heart ) physical examination . TMC435 take oral capsule 150 mg per day . Peginterferon ( Pegasys ) give injection 180 Âµg week . Ribavirin take tablet ( Copegus ) twice day dose depend patient 's body weight .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients participate placebo arm TMC435 study achieve undetectable HCV RNA level end treatment relapse within 1 year end treatment OR Patients receive shortterm directacting antiviral therapy Tibotecsponsored study . Liver disease stage document liver biopsy require within 3 year prior screen unless contraindicate . Infection human immunodeficiency virus . Liver disease relate hepatitic C infection . Significant laboratory abnormality active disease . Pregnant plan become pregnant . Prematurely stop medication previous TMC435 study noncompliance safety reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>TMC435-TiDP16-C213</keyword>
	<keyword>TMC435-C213</keyword>
	<keyword>TMC435</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>